What changed
Added the source-verified Claim Check to the structured claim/source/change registry.
Source record · FDA labeling · reviewed July 16, 2026
The approval is real, but it is much narrower than the viral claim.
The circulating claim“PT-141 is FDA-approved as a general libido peptide for men and women.”
What the source record says
Vyleesi is FDA-approved for a narrow population: premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its label says it is not indicated for men, postmenopausal women, or enhancement of sexual performance.
Why the claim misleads
A product-specific approval is being widened into a general claim about an ingredient, multiple populations, and an outcome the label does not support.
Correction
The approval is real, but it is much narrower than the viral claim.
Primary sources
FDA-approved Vyleesi labelingOpen source ↗Bremelanotide / PT-141 library entryOpen source ↗What would change our answer
A well-controlled human study tied to the exact product, population, route, and claimed outcome could change the answer. Mechanism, anecdotes, or a different product cannot substitute for that evidence.
Version history · 1 entry
- v1 · 2026-07-16Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.